Relationship between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease

1988 ◽  
Vol 25 (1-2) ◽  
pp. 115-123 ◽  
Author(s):  
N. K. Boughton-Smith ◽  
J. L. Wallace ◽  
B. J. R. Whitle
2015 ◽  
Vol 114 (5) ◽  
pp. 734-745 ◽  
Author(s):  
Yukiko Naito ◽  
Xu Ji ◽  
Shigehiro Tachibana ◽  
Satoko Aoki ◽  
Mami Furuya ◽  
...  

AbstractThe aim of this study was to investigate the effects of the administration of oral arachidonic acid (AA) in rats with or without dextran sulphate sodium (DSS)-induced inflammatory bowel disease. Male Wistar rats were administered AA at 0, 5, 35 or 240 mg/kg daily by gavage for 8 weeks. Inflammatory bowel disease was induced by replacing drinking water with 3 % DSS solution during the last 7 d of the AA dosing period. These animals passed loose stools, diarrhoea and red-stained faeces. Cyclo-oxygenase-2 concentration and myeloperoxidase activity in the colonic tissue were significantly increased in the animals given AA at 240 mg/kg compared with the animals given AA at 0 mg/kg. Thromboxane B2 concentration in the medium of cultured colonic mucosae isolated from these groups was found to be dose-dependently increased by AA, and the increase was significant at 35 and 240 mg/kg. Leukotriene B4 concentration was also significantly increased and saturated at 5 mg/kg. In addition, AA at 240 mg/kg promoted DSS-induced colonic mucosal oedema with macrophage infiltration. In contrast, administration of AA for 8 weeks, even at 240 mg/kg, showed no effects on the normal rats. These results suggest that in rats with bowel disease AA metabolism is affected by oral AA, even at 5 mg/kg per d, and that excessive AA may aggravate inflammation, whereas AA shows no effects in rats without inflammatory bowel disease.


2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Zhongquan Xin ◽  
Zhenya Zhai ◽  
Hongrong Long ◽  
Fan Zhang ◽  
Xiaojun Ni ◽  
...  

Liver disorder often occurs in patients with inflammatory bowel disease (IBD); however, the changes in IBD-induced liver disorder at the intrinsic molecular level (chiefly metabolites) and therapeutic targets are still poorly characterized. First, a refined and translationally relevant model of DSS chronic colitis in C57BL/6 mice was established, and cecropin A and antibiotics were used as interventions. We found that the levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in the liver tissues of mice were highly increased in the context of DSS treatment but were lowered by cecropin A and antibiotics. Subsequently, an untargeted metabolomics analysis was performed by UPLC–Orbitrap–MS/MS to reveal the metabolic profile and attempt to find the potential therapeutic targets of the liver disorders that occur in IBD. Notably, 133 metabolites were identified by an integrated database. Metabolism network and pathway analyses demonstrated that the metabolic disturbance of the liver in IBD mice was mainly enriched in bile acid metabolism, arachidonic acid metabolism, amino acid metabolism, and steroid hormone biosynthesis, while those disturbances were regulated or reversed through cecropin A and antibiotic treatment. Furthermore, the top 20 metabolites, such as glutathione, maltose, arachidonic acid, and thiamine, were screened as biomarkers via one-way analysis of variance (one-way ANOVA, p<0.05) coupled with variable importance for project values (VIP >1) of orthogonal partial least-squares discriminant analysis (OPLS-DA), which could be upregulated or downregulated with the cecropin A and antibiotics treatment. Spearman correlation analysis showed that the majority of the biomarkers have a significant correlation with cytokines (TNF-α, IL-1β, IL-6, and IL-10), indicating that those biomarkers may act as potential targets to interact directly or indirectly with cecropin A and antibiotics to affect liver inflammation. Collectively, our results extend the understanding of the molecular alteration of liver disorders occurring in IBD and offer an opportunity for discovering potential therapeutic targets in the IBD process.


2012 ◽  
Vol 12 (6) ◽  
pp. 484-492 ◽  
Author(s):  
Kazunari Ozaki ◽  
Hirofumi Makino ◽  
Motokuni Aoki ◽  
Takashi Miyake ◽  
Natsuki Yasumasa ◽  
...  

2020 ◽  
Vol 34 (11) ◽  
pp. 3019-3028
Author(s):  
Ningning Yang ◽  
Guoying Liang ◽  
Jing Lin ◽  
Sijia Zhang ◽  
Qiuchi Lin ◽  
...  

2019 ◽  
Vol 156 (6) ◽  
pp. S-1305-S-1306
Author(s):  
Shannon Glaser ◽  
Lixian Chen ◽  
April O'Brien ◽  
Walter Cromer ◽  
Gianfranco Alpini ◽  
...  

2007 ◽  
Vol 102 (3) ◽  
pp. 761-772 ◽  
Author(s):  
Mireille Basselin ◽  
Nelly E. Villacreses ◽  
Ho-Joo Lee ◽  
Jane M. Bell ◽  
Stanley I. Rapoport

Sign in / Sign up

Export Citation Format

Share Document